Edison Pharmaceuticals, Inc. was founded with one goal: to develop a clinically meaningful treatment for inherited mitochondrial disease. Mitochondrial disease is most often diagnosed in childhood, is highly debilitating, and often results in early death. When mitochondrial disease progresses to adulthood, it is significantly disabling and also life-shortening.

The term inherited mitochondrial disease actually represents a family of diseases. While they are known by a variety of names, they share a common feature—a defect in how energy is made and regulated. Today there are over 2,000 known genetic defects that cause mitochondrial disease. There are no approved drugs to treat mitochondrial disease.

In 2005, patient families, physicians, scientists, and foundations joined together around a single mission: to build a company that would translate promising laboratory findings into clinically meaningful drugs. Since the beginning of operations in late 2006, Edison has placed three new drugs into clinical development. EPI-743 is now in phase 2B/3 pivotal clinical trials for inherited mitochondrial disease. EPI-A0001 has now recently completed a phase 2A study in the mitochondrial disease Friedreich's ataxia where it has improved neurological outcome measures.

To accomplish its mission, Edison built a discovery and translation research platform that centers on the regulation of energy metabolism, and its clinical measurement. The company holds over 100 patents that span cell biology, chemistry, and methods for drug discovery.

Edison Pharmaceuticals, Inc. is headquartered in Mountain View, California and has European offices in The Netherlands. In Mountain View, the company occupies 15,000 square feet of state-of-the-art research and development space.